These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27489350)

  • 1. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
    Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
    Shu XR; Wu J; Sun H; Chi LQ; Wang JH
    Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
    Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
    J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Preexisting Rare
    Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
    Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S; Tang Y; Yan M; Jiang W
    Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the
    Jiang W; Wu Y; He T; Zhu H; Ke G; Xiang L; Yang H
    Mol Cancer Ther; 2020 Feb; 19(2):337-347. PubMed ID: 31666350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
    Krishnamurthy S; Yoda H; Hiraoka K; Inoue T; Lin J; Shinozaki Y; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Sci; 2021 Mar; 112(3):1141-1149. PubMed ID: 33377228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR‑519d‑3p/HIF‑2α axis increases the chemosensitivity of human cervical cancer cells to cisplatin via inactivation of PI3K/AKT signaling.
    Jiang L; Shi S; Li F; Shi Q; Zhong T; Zhang H; Xia Y
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
    Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB
    J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Zeng SX; Zhu Y; Ma AH; Yu W; Zhang H; Lin TY; Shi W; Tepper CG; Henderson PT; Airhart S; Guo JM; Xu CL; deVere White RW; Pan CX
    Clin Cancer Res; 2017 Nov; 23(21):6580-6591. PubMed ID: 28808038
    [No Abstract]   [Full Text] [Related]  

  • 17. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
    Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP; Lee CH; Ying TH; Lin CL; Lin CL; Hsueh JT; Hsieh YH
    Oncotarget; 2015 Oct; 6(30):28851-66. PubMed ID: 26311737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.
    Leisching GR; Loos B; Botha MH; Engelbrecht AM
    Toxicology; 2015 Sep; 335():72-8. PubMed ID: 26201060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.